OBM_Logo_Orange_White_RGB-4

Close

Who We Are
Our Innovations
Investor Relations
Contact Us

Who we are
Our Innovations
Content Hub
Investor Relations

Our Approach
Our People
Careers

Pipeline
Therapeutic Areas
AVIM Therapy
Virtue® SAB

Overview
News & Events
Stock Quote & Chart
Analyst Coverage
Corporate Governance
Financial & Filings
IR Resources

News & Events

Our Content Hub

Who we are
Our Innovations
Content Hub
Investor Relations

Our Approach
Our People
Careers

Pipeline
Therapeutic Areas
AVIM Therapy
Virtue® SAB

Overview
News & Events
Stock Quote & Chart
Analyst Coverage
Corporate Governance
Financial & Filings
IR Resources

Our Content Hub

Unlocking the Value of Virtue SAB with the Achievement Milestones

AVIM Therapy Breakthrough Device Designation Shareholder Implications

Yesterday’s FDA Breakthrough Device Designation News

Virtue SAB IDE Approval and What It Means for OBIO Shareholders

OBIO | NYSE Interview: A Shareholder Guide and Key Takeaways

A Closer Look at Last Week’s Financing News — and What Comes Next

Strategic Recaps: The Power of Partnership and Future of AVIM Therapy

OBIO | AVIM Publications and Presentations Supplementary Explanation

AVIM Therapy: A Purpose-Built Solution for a Large, Underserved Patient Population

First Quarter 2025 Business Highlights

Recent
Popular
Categories

Lists by Topic

Clinical (3)
Regulatory (3)
Corporate (2)
Finance (2)

Posts by Topic

Clinical (3)
Regulatory (3)
Corporate (2)
Finance (2)

Recent Posts

Who We Are
Our Approach
Our People
Careers
Our Innovations
Pipeline
Therapeutic Areas
Platforms
Virtue® SAB
BackBeat CNT™
FreeHold Retractors
For Investors
Company Overview
Stock Information
Corporate Governance
Financials & Filings
Investor Relations
Contact Us

© 2025 Orchestra BioMed Inc. Virtue®, BackBeat CNT™ FreeHold Duo®, FreeHold Trio® and Orchestra BioMed™ are trademarks of Orchestra BioMed.
All other trademarks are trademarks of their respective owners.
SM-0020 Rev 01